DRUGS MADE IN AMERICA ACQUISITION CORP
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$10.89
+0.05%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
+0.0%
3 months
+1.7%
6 months
+3.0%
1 year
+5.5%
Year to date
+5.0%
52-week range
$10.31 – $10.89
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$264.4M
P/E
43.4
P/B
-35.7
P/S
—
Revenue
$0
Net income
$6.09M
Diluted EPS
0.19
Gross margin
—
Net margin
—
Return on equity
-83.00%
Total debt
$950K
Cash
$20.28K
Free cash flow
-$517.15K
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $0 | $1.73M | — | — | -$244.61K |
| Mar 31, 2026 | $0 | $1.97M | — | — | -$91.25K |
| Dec 31, 2025 | $0 | $212.96K | — | — | -$125.18K |
| Sep 30, 2025 | $0 | $2.18M | — | — | -$56.11K |
| Jun 30, 2025 | $0 | $2.29M | — | — | -$106.66K |
| Mar 31, 2025 | $0 | $1.25M | — | — | -$251.24K |
| Dec 31, 2024 | — | — | — | — | — |
| Sep 30, 2024 | $0 | -$144.93K | — | — | -$57.23K |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent DMAA news
All market newsNo ticker-linked stories are in the current archive.